Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic β-cells

European Journal of Endocrinology

Volumn 152, Issue 1, 2005, Pages 103-112

  Haugaard, Steen B ^a   Andersen, Ove ^a   Dela, Flemming ^b   Holst, Jens Juul ^c   Storgaard, Heidi ^b   Fenger, Mogens ^a   Iversen, Johan ^a   Madsbad, Sten ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FATTY ACID; GLUCOSE; INDINAVIR; LAMIVUDINE; LIPID; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRITIUM; ZIDOVUDINE;

ARTICLE; BODY FAT; CALORIMETRY; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; FATTY ACID BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE OXIDATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIMB; LIPID METABOLISM; LIPID OXIDATION; LIVER PARENCHYMA; MUSCLE TISSUE; PANCREAS ISLET BETA CELL; PREVALENCE; PRIORITY JOURNAL; TRUNK;

ADULT; ALANINE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; BODY COMPOSITION; CHOLESTEROL, HDL; FATTY ACIDS, NONESTERIFIED; GLUCAGON; GLUCOSE; GLYCEROL; HIV; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN; ISLETS OF LANGERHANS; LACTIC ACID; LIVER; MALE; MIDDLE AGED; MUSCLE, SKELETAL; TRIGLYCERIDES; TRITIUM;

EID: 13244265847     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01835     Document Type: Article

References (49)

1. Chen D, Misra A & Garg A. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. Journal of Clinical Endocrinology and Metabolism 2002 87 4845-4856.
2. Carr A, Emery S, Law M, Puls R, Lundgren JD & Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003 361 726-735.
3. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL & Eckel RH. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001 15 1993-2000.
4. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J & Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. Journal of Acquired Immune Deficiency Syndrome 2000 25 312-321.
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999 353 2093-2099.
6. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D'Agostino RB & Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clinical Infectious Diseases 2001 32 130-139.
7. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL & Gerich JE. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003 52 918-925.
8. Hadigan C, Borgonha S, Rabe J, Young V & Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 2002 51 1143-1147.
9. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, Jarvinen A, Ristola M & Yki-Jarvinen H. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002 16 2183-2193.
10. Gan SK, Samaras K, Thompson CH, Kraegen EW, Carr A, Cooper DA & Chisholm DJ. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 2002 51 3163-3169.
11. Luzi L, Perseghin G, Tambussi G, Meneghini E, Scifo P, Pagliato E, Del Maschio A, Testolin G & Lazzarin A. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. American Journal of Physiology, Endocrinology and Metabolism 2003 284 E274-E280.
12. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S & Andersen O. Increased expression of TNF-α, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. American Journal of Physiology, Endocrinology and Metabolism 2003 285 E1072-E1080.
13. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998 12 F51-F58.
14. Andersen O, Haugaard SB, Andersen UB, Friis-Moller N, Storgaard H, Volund A, Nielsen JO, Iversen J & Madsbad S. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism 2003 52 1343-1353.
15. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. Journal of Applied Physiology 1983 55 628-634.
16. Fogh-Andersen N & D'Orazio P. Proposal for standardizing direct-reading biosensors for blood glucose. Clinical Chemistry 1998 44 655-659.
17. Holst JJ. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours. Diabetologia 1983 24 359-365.
18. Hother-Nielsen O, Henriksen JE, Holst JJ & Beck-Nielsen H. Effects of insulin on glucose turnover rates in vivo: isotope dilution versus constant specific activity technique. Metabolism 1996 45 82-91.
19. Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S & Vaag AA. Early differential defects of insulin secretion and action in 19-year-old Caucasian men who had low birth weight. Diabetes 2002 51 1271-1280.
20. Del Prato S, Bonadonna RC, Bonora E, Gulli G, Solini A, Shank M & DeFronzo RA. Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. Journal of Clinical Investigation 1993 91 484-494.
21. Matsuda M & DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 22 1462-1470.
22. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC & Palmer JP. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993 42 1663-1672.
23. Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR). Drugs 1999 58 (Suppl 1) 7-10.
24. Murata H, Hruz PW & Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. Journal of Biological Chemistry 2000 275 20251-20254.
25. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M & Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002 16 F1-F8.
26. Hruz PW, Murata H, Qiu H & Mueckler M. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 2002 51 937-942.
27. Rossetti L, Lee YT, Ruiz J, Aldridge SC, Shamoon H & Boden G. Quantitation of glycolysis and skeletal muscle glycogen synthesis in humans. American Journal of Physiology 1993 265 E761-E769.
28. Vaag A, Alford F, Henriksen FL, Christopher M & Beck-Nielsen H. Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM. Diabetologia 1995 38 326-336.
29. Blaak EE, Aggel-Leijssen DP, Wagenmakers AJ, Saris WH & Van Baak MA. Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. Diabetes 2000 49 2102-2107.
30. Kelley DE & Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000 49 677-683.
31. Yki-Jarvinen H, Puhakainen I & Koivisto VA. Effect of free fatty acids on glucose uptake and nonoxidative glycolysis across human forearm tissues in the basal state and during insulin stimulation. Journal of Clinical Endocrinology and Metabolism 1991 72 1268-1277.
32. Behrens GM, Boerner AR, Weber K, Van den Hoff J, Ockenga J, Brabant G & Schmidt RE. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. Journal of Clinical Investigation 2002 32 1319-1327.
33. van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, Reiss P & Sauerwein HP. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001 15 2093-2100.
34. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J & Yki-Jarvinen H. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000 49 749-758.
35. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J & Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. Journal of Clinical Endocrinology and Metabolism 2002 87 3023-3028.
36. Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ & DeFronzo RA. Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. American Journal of Physiology, Endocrinology and Metabolism 2002 283 E1135-E1143.
37. Shah P, Basu A, Basu R & Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. American Journal of Physiology 1999 277 E283-E290.
38. Staehr P, Hother-Nielsen O, Levin K, Holst JJ & Beck-Nielsen H. Assessment of hepatic insulin action in obese type 2 diabetic patients. Diabetes 2001 50 1363-1370.
39. Hadigan C, Rabe J, Meininger G, Aliabadi N, Breu J & Grinspoon S. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. American Journal of Clinical Nutrition 2003 77 490-494.
40. Abbasi F, McLaughlin T, Lamendola C & Reaven GM. Insulin regulation of plasma free fatty acid concentrations is abnormal in healthy subjects with muscle insulin resistance. Metabolism 2000 49 151-154.
41. Boden G, Chen X, Ruiz J, White JV & Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. Journal of Clinical Investigation 1994 93 2438-2446.
42. Bergman RN, Finegood DT & Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. European Journal of Clinical Investigation 2002 32 (Suppl 3) 35-45.
43. Orland MJ & Permutt MA. Comparative modulations of insulin secretion, pancreatic insulin content, and proinsulin mRNA in rats. Effects of 50% pancreatectomy and dexamethasone administration. Diabetes 1991 40 181-189.
44. Christiansen E, Tibell A, Rasmussen K, Tyden G & Madsbad S. Defects in quantitative and qualitative beta-cell function following successful segmental pancreas transplantation. Danish-Swedish Study Group of Metabolic Effect of Pancreas Transplantation (DSSGMEPT). Transplantation Proceedings 1993 25 1186-1189.
45. Porte D Jr. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 1991 40 166-180.
46. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M & Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999 13 F63-F70.
47. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA & Bloom SR. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999 48 86-93.
48. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R & Cusi K. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003 52 2461-2474.
49. Tripathy D, Wessman Y, Gullstrom M, Tuomi T & Groop L. Importance of obtaining independent measures of insulin secretion and insulin sensitivity during the same test: results with the Botnia clamp. Diabetes Care 2003 26 1395-1401.